Mabion S.A.
MAB.WA - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$129.3M
Close$
$-5.32
167.2% downside
Current Fair Value
167.2% downsideOvervalued by 167.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $129.30 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-3.87 |
| Beta | 0.38 |
| Outstanding Shares | 16,162,326 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -2.29 |
|---|---|
| PEG | 73.27 |
| Price to Sales | 7.92 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
September 15, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$7.00 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 17, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$5.00 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Mabion S.A.
202 employees
CEO: Krzysztof Kaczmarczyk
Mabion S.A. is a Polish biopharmaceutical firm dedicated to pioneering the development of biological drugs, primarily leveraging monoclonal antibody technology. The company oversees the full spectrum from research and development to the ...